BCG Immunotherapy: What’s New?

Posted by Erik P. Castle, MD, FACS | Mar 2015

Dr. Erik P. Castle spoke at the 23rd annual Perspectives in Urology Point • Counterpoint meeting on Saturday, November 15, 2014 on “BCG Immunotherapy: What’s New?”.

Presentation

Keywords: Bacillus Calmette-Guérin (BCG), bladder cancer, immune therapy, cytology, lymphocytes, Th1, Th2

How to cite: Castle, Erik P. “BCG Immunotherapy: What’s New?” Grand Rounds in Urology. November 15, 2014. Accessed Apr 2024. https://dev.grandroundsinurology.com/bladder-cancer-erik-p-castle-bcg-immunotherapy/.

About The Author

Erik P. Castle, MD, FACS

Dr. Erik P. Castle is a Professor of Urology at the Mayo Clinic College of Medicine. His surgical expertise includes minimally invasive urologic oncology, including robot-assisted radical cystectomy, prostatectomy, retroperitoneal lymph node dissection, and partial nephrectomy. He has demonstrated many of these procedures internationally, as he pioneered robot cystectomy as well as robot RPLND. He directs the International Laparoscopic Nephrectomy Program in Mexico on behalf of the American Urologic Association (AUA), and also serves on several committees and guideline panels within the American Urologic Association. He is on the Early Detection of Prostate Cancer Panel for the National Comprehensive Cancer Network (NCCN) as well. Dr. Castle’s research interests include prostate cancer, bladder cancer, and kidney cancer. He is the Director of the Desert Mountain Care Prostate Cancer Research Fund and is the principal investigator of his lab housed at the Mayo Clinic Collaborative Research Building. His basic science research is focused on novel secondary hormonal therapies of prostate cancer and apoptotic pathways related to manipulations of the androgen and estrogen receptors. He also directs the prospectively collected genitourinary biorepository at Mayo Clinic Arizona, which houses over 40,000 specimens.

Join the GRU Community

- Why Join? -

CARDEN JENNINGS PUBLISHING CO., LTD.

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

PDF Embedder Test Jan 2022
Genetic Testing and Prostate Cancer – Welcome Jan 2022
Current Status of PSMA Diagnostics Aug 2021
Genetic Testing and Prostate Cancer Aug 2021
What’s New in Active Surveillance for Prostate Cancer in 2021 Aug 2021

BCG Immunotherapy: What’s New?

About The Author

Erik P. Castle, MD, FACS

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

Exercise & Wellness

BCG Immunotherapy: What’s New?

About The Author

Erik P. Castle, MD, FACS

Related Posts

Adaptive Immune Resistance to Intravesical BCG in NMIBC: Implications for Ongoing and Future BCG Unresponsive Clinical Trials

BCG Maintenance Should Be Less Intense

Disparities in the Use of Continent Urinary Diversions after Radical Cystectomy for Bladder Cancer

Robotic Cystectomy and ICUD for Muscle Invasive Bladder Cancer

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard – Your Courses

Recent Updates

Exercise & Wellness

– Account Dashboard
– Your Courses